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BACKGROUND:Patterns of second primary cancers (SPCs) following first primary lung cancers (FPLCs) may provide aetiological insights
into FPLC.
METHODS:Cases of FPLCs in 13 cancer registries in Europe, Australia, Canada, and Singapore were followed up from the date of FPLC
diagnosis to the date of SPC diagnosis, date of death, or end of follow-up. Standardised incidence ratios (SIRs) were calculated to
estimate the magnitude of SPC development following squamous cell carcinoma (SCC), small cell lung carcinoma (SCLC), and
adenocarcinoma (ADC).
RESULTS: Among SCC patients, male SIR¼1.58 (95% confidence interval (CI)¼1.50–1.66) and female SIR¼2.31 (1.94–2.72) for
smoking-related SPC. Among SCLC patients, the respective ratios were 1.39 (1.20–1.60) and 2.28 (1.73–2.95), and among ADC
patients, they were 1.73 (1.57–1.90) and 2.24 (1.91–2.61). We also observed associations between first primary lung ADC and
second primary breast cancer in women (SIR¼1.25, 95% CI¼1.05–1.48) and prostate cancer (1.56, 1.39–1.79) in men.
CONCLUSION: The FPLC patients carried excess risks of smoking-related SPCs. An association between first primary lung ADC and
second primary breast and ovarian cancer in women at younger age and prostate cancers in men may reflect an aetiological role of
hormones in lung ADC.
British Journal of Cancer (2010) 102, 1190–1195. doi:10.1038/sj.bjc.6605616 www.bjcancer.com
& 2010 Cancer Research UK
Keywords: lung cancer; SPCs; sex differences
                                                                         
Lung cancer is the most common cancer in the world, representing
12.4% of all new cancer cases in the year 2002 (Parkin et al, 2005),
its main risk factor being tobacco smoking. Other risk factors
are involuntary smoking and occupational exposure to agents
such as asbestos, radon, arsenic, and silica dust; suspected risk
factors include air pollution and dietary factors, notably low
consumption of fruits and vegetables (Teppo et al, 2001; Spitz et al,
2006; World Cancer Research Fund, 2007).
There are four major lung cancer subtypes: squamous cell
carcinoma (SCC), large cell carcinoma, adenocarcinoma (ADC),
and small cell lung carcinoma (SCLC), comprising over 90% of
all cases (Spitz et al, 2006). Although smoking is associated with
all histological types of lung cancer, ADC has a weaker association
with smoking than other types in terms of smoking status,
intensity, duration, age at start, dose, and years since quitting
(Barbone et al, 1997).
Several studies examined second primary cancers (SPCs)
following lung cancer (Levi et al, 1999; Teppo et al, 2001;
Liu et al, 2002; Duchateau and Stokkel, 2005), but not by gender.
As lung cancer epidemiology is different in men and women,
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yaetiology may also differ and be reflected in SPCs. This study includes
three major histological types of lung cancer: SCC, SCLC, and
ADC. We have examined differences in the pattern of SPCs between
men and women who had a first primary lung cancer (FPLCs).
MATERIALS AND METHODS
An international multicentre study was initiated to incorporate large
cancer registries that have been in operation for at least 25 years, to
conduct a systematic analysis of SPCs (Brennan et al, 2005; Scelo
et al, 2006). The registries included New South Wales in Australia,
British Columbia, Manitoba and Saskatchewan in Canada,
Denmark, Finland, Iceland, Norway, Scotland, Singapore, Slovenia,
Sweden, and Zaragoza in Spain. These registries had cancer data
covering different time periods within the period 1943–2000. A high
degree of ascertainment completeness by the registry is suggested by
consistent inclusion in subsequent volumes of Cancer Incidence in
Five Continents (Parkin et al,2 0 0 2 ) .
Data were provided by each cancer registry on all first primary
cancers, including age and sex of each subject, diagnosis and date
of the first primary cancer, follow-up for mortality, and diagnosis
and date of the SPCs, if any. In this study, any different cancer
codes used by registries were systematically converted into
International Classification of Disease, Ninth Revision (ICD-9).
We analysed the occurrence of SPC in survivors of lung cancer
(ICD-9: 162). Coding of multiple primaries in the cancer registries
followed a common set of rules proposed by the International
Association of Cancer Registries and the International Agency for
Research on Cancer (IARC) (Muir and Percy, 1991). These define
primary cancer as one that originates in a primary site or tissue
and is thus neither an extension nor a recurrence nor a metastasis.
Only one tumour was recognised as arising in an organ or pair of
organs or tissue as defined by the three-character category of the
ICD or the topography of the ICD-O. Non-melanoma skin cancer
(ICD-9: 173) was excluded because of the inconsistency in
reporting across registries. We defined smoking-related cancers
according to the most recent IARC monograph on the subject as
cancers of the lip (ICD-9: 140), tongue (141), salivary gland (142),
mouth (143–145), oropharynx (146), nasopharynx (147), hypo-
pharynx (148), pharynx unspecified (149), oesophagus (150),
stomach (151), liver (155), pancreas (157), nose and nasal cavity
(160), larynx (161), bladder (188), and kidney (189), and as
leukaemia (204–208) (IARC Working Group, 2004).
All cases of FPLC were followed up from the date of the first lung
cancer diagnosis (1943–2000) to the date of SPC (1943–2000), date
of death, or end of follow-up (1992–2000). To assess the potential
excess occurrence of SPC, the numbers of SPCs observed and
expected were used to estimate the standardised incidence ratios
(SIRs). The SIRs adjusted for age, sex, year, and registry were
calculated using indirect standardisation methods (Brennan et al,
2005). The expected number was calculated from accumulated
person-years and age-, sex-, and calendar period-specific cancer
incidence rates in each of the cancer registries.
Table 1 Descriptive characteristics of first primary lung cancer patients from 13 cancer registries
Squamous cell carcinoma Small cell carcinoma Adenocarcinoma excluding bronchioalveolar
Women Men Women Men Women Men
N % N % N % N % N % N %
Total 20468 113197 15639 37663 27502 44090
Age at diagnosis (year)
o56 2990 14.61 15128 13.36 2865 18.32 6577 17.46 6903 25.10 8528 19.34
56–65 6021 29.42 37568 33.19 5188 33.17 12960 34.41 8088 29.41 14395 32.65
66–74 7184 35.10 40731 35.98 5227 33.42 12553 33.33 7669 27.89 14225 32.26
75+ 4273 20.88 19770 17.47 2359 15.08 5573 14.80 4842 17.61 6942 15.75
Calendar period at diagnosis
B1975 1966 9.61 25719 22.72 555 3.55 4590 12.19 2779 10.10 5444 12.35
1975–1983 4933 24.10 33279 29.40 3371 21.56 10399 27.61 5428 19.74 10350 23.47
1984–1990 6318 30.87 29442 26.01 5278 33.75 11958 31.75 8175 29.73 13281 30.12
1991B 7251 35.43 24757 21.87 6435 41.15 10716 28.45 11120 40.43 15015 34.06
Follow-up period
o12 months 13342 65.18 69243 61.17 11168 71.41 28757 76.35 17899 65.08 20704 46.96
1–4 year 5408 26.42 33111 29.25 3921 25.07 7963 21.14 7129 25.92 10260 23.27
5–9 year 959 4.69 5833 5.15 298 1.91 518 1.38 1407 5.12 1817 4.12
10+ year 759 3.71 5010 4.43 252 1.61 425 1.13 1067 3.88 1309 2.97
Registries
Australia, NSW (1972–1997) 2076 10.14 10893 9.62 2032 12.99 5076 13.48 2517 9.15 5331 12.09
Canada, British Columbia (1970–1998) 2313 11.30 7169 6.33 2092 13.38 3173 8.42 3617 13.15 4499 10.20
Canada, Manitoba (1970–1998) 675 3.30 3004 2.65 649 4.15 1241 3.30 1180 4.29 1766 4.01
Canada, Saskatchewan (1967–1998) 409 2.00 1924 1.70 267 1.71 760 2.02 571 2.08 783 1.78
Denmark (1943–1997) 3891 19.01 21299 18.82 2926 18.71 5682 15.09 5762 20.95 7611 17.26
Finland (1953–1998) 1386 6.77 19914 17.59 1177 7.53 8283 21.99 2027 7.37 5221 11.84
Iceland (1955–2000) 152 0.74 340 0.30 173 1.11 224 0.59 324 1.18 289 0.66
Norway (1953–1999) 1591 7.77 10374 9.16 1875 11.99 4695 12.47 3032 11.02 5333 12.10
Singapore Chinese (1968–1992) 504 2.46 2697 2.38 185 1.18 793 2.11 994 3.61 1550 3.52
Slovenia (1961–1998) 303 1.48 5853 5.17 207 1.32 1073 2.85 774 2.81 1551 3.52
Spain, Zaragoza (1978–1998) 56 0.27 1975 1.74 17 0.11 696 1.85 101 0.37 635 1.44
Sweden (1961–1998) 2223 10.86 12023 10.62 0 0.00 0 0.00 3971 14.44 5535 12.55
UK, Scotland (1975–1996) 4889 23.89 15732 13.90 4039 25.83 5967 15.84 2632 9.57 3986 9.04
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number and estimate the gender effect on SIRs (Richiardi et al,
2007). The cumulative risk of second smoking- or non-smoking-
related cancers was calculated by taking into account death
as a competing risk (Gooley et al, 1999). The absolute excess risk
(AER) – a measure for estimating the absolute burden or
magnitude of a health problem – was defined as the difference
between the observed and expected number of SPCs divided by the
total number of person-years at risk, and is expressed as per
100000person-years (Travis, 2006).
RESULTS
Table 1 summarises the characteristics of patients with a
primary lung cancer by histology. A total of 63609 females with
100036person-years of observation and 194950 males with
311666person-years of observation were identified across the
13 cancer registries. The mean follow-up periods were 1.6 years for
both men and women. During the follow-up, a total of 5383 SPCs
were recorded. Among the 258559 lung cancers, 3259 SCCs (2.4%),
557 SCLCs (1.0%), and 1567 ADCs (2.2%) developed an SPC,
indicating an excess risk of SPCs of 36% for women and 25% for
men (data not shown).
Table 2 shows the SIR and AER of the selected SPCs by sex and
histology. The detailed SIRs for each SPC site and by histology are
listed in Appendix Table A1. The SIRs for smoking-related second
cancers were 2.31 (95% confidence interval (CI)¼1.94–2.72) for
female and 1.58 (95% CI¼1.50–1.66) for male SCC patients; 2.28
(95% CI¼1.73–2.95) for female and 1.39 (95% CI¼1.20–1.60) for
male SCLC patients; and 2.24 (95% CI¼1.91–2.61) for female and
1.73 (95% CI¼1.57–1.90) for male ADC patients. In addition to the
relative measures, the absolute measure, AERs, were higher
in smoking-related cancers than in non-smoking-related cancers in
SCC and SCLC, whereas the burden was almost the same in ADC.
Associations with second primary breast cancer (SIR¼1.25, 95%
CI¼1.05–1.48) among women, prostate cancer (SIR¼1.56, 95%
CI¼1.39–1.79) among men, and second primary thyroid cancer
among both men (SIR¼3.43, 95% CI¼1.57–8.62) and women
(SIR¼4.87, 95% CI¼2.88–7.69) were observed after first primary
lung ADC (P-value for heterogeneity among three histological types
o0.05); such associations were not observed for lung SCC and SCLC.
Figure 1 shows the observed cumulative risk for smoking- and
non-smoking-related SPCs by sex and histology, taking death into
Table 2 Numbers of cases (Obs), standardised incidence ratio (SIR) and absolute excess risk (AER) per 100000person-years of selected second primary
cancers after lung cancer by sex and histology
Squamous cell
carcinoma
Small cell
carcinoma
Adenocarcinoma excluding
bronchioalveolar
Cancer sites (ICD 9th revision) Obs SIR 95% CI AER Obs SIR 95% CI AER Obs SIR 95% CI AER
Women PY¼34344 PY¼16763 PY¼48929
All but non-melanoma skin 377 1.28 (1.16–1.42) 242.55 149 1.16 (0.98–1.36) 119.65 555 1.49 (1.37–1.62) 374.30
Smoking-related cancers 142 2.31 (1.94–2.72) 234.27 58 2.28 (1.73–2.95) 194.47 164 2.24 (1.91–2.61) 185.80
Head and neck 31 5.69 (3.87–8.08) 74.41 9 3.49 (1.59–6.63) 38.31 13 1.85 (0.99–3.17) 12.23
Oesophagus (150) 14 3.31 (1.81–5.56) 28.45 6 3.30 (1.21–7.18) 24.95 7 1.72 (0.69–3.55) 6.01
Bladder and kidney 40 2.31 (1.65–3.14) 65.95 18 2.45 (1.45–3.88) 63.59 69 3.32 (2.58–4.21) 98.59
Leukaemias (204–208) 9 1.28 (0.58–2.42) 5.73 9 3.06 (1.40–5.82) 36.14 22 2.50 (1.57–3.79) 27.00
Other smoking-related cancers 37 1.94 (1.36–2.67) 52.14 10 1.45 (0.70–2.67) 18.58 41 1.93 (1.38–2.62) 40.34
Colorectal (153, 154) 41 0.84 (0.60–1.14)  22.74 14 0.67 (0.36–1.12)  41.14 74 1.26 (0.99–1.58) 31.21
Colon (153) 30 0.90 (0.61–1.29)  9.71 9 0.63 (0.29–1.19)  31.53 56 1.43 (1.08–1.86) 34.42
Rectum (154) 11 0.70 (0.35–1.24)  13.73 5 0.75 (0.24–1.74)  9.94 18 0.93 (0.55–1.46)  2.77
Non-smoking-related cancer 194 1.06 (0.91–1.22) 31.03 77 0.93 (0.74–1.16)  33.66 317 1.32 (1.18–1.47) 157.14
Female breast (174) 87 1.09 (0.88–1.35) 20.92 29 0.77 (0.52–1.11)  51.68 135 1.25 (1.05–1.48) 55.12
Cervix uteri (180) 11 1.31 (0.65–2.35) 7.58 6 1.56 (0.57–3.41) 12.85 12 1.07 (0.55–1.87) 1.63
Corpus uteri (182) 8 0.43 (0.19–0.85)  30.88 3 0.36 (0.07–1.05)  31.82 19 0.76 (0.46–1.18)  12.52
Ovary (183) 23 1.47 (0.93–2.21) 21.41 9 1.28 (0.59–2.43) 11.74 28 1.37 (0.91–1.98) 15.52
Thyroid gland (193) 6 2.48 (0.91–5.40) 10.43 3 2.64 (0.54–7.71) 11.12 18 4.87 (2.88–7.69) 29.23
Other non-smoking-related cancers 59 1.01 (0.76–1.30) 1.57 27 1.10 (0.72–1.60) 14.12 105 1.47 (1.20–1.77) 68.16
Men PY¼212428 PY¼34293 PY¼64945
All but non-melanoma skin 2882 1.21 (1.16–1.25) 231.99 408 1.16 (1.05–1.27) 160.26 1012 1.47 (1.38–1.56) 498.00
Smoking-related cancers 1454 1.58 (1.50–1.66) 250.63 186 1.39 (1.20–1.60) 151.44 428 1.73 (1.57–1.90) 277.11
Head and neck 340 2.53 (2.27–2.81) 96.76 33 1.50 (1.04–2.11) 32.26 77 2.01 (1.59–2.51) 59.57
Oesophagus (150) 93 1.78 (1.44–2.18) 19.18 12 1.46 (0.75–2.55) 11.03 27 1.91 (1.26–3.09) 19.76
Bladder and kidney 565 1.87 (1.72–2.03) 123.83 70 1.62 (1.26–2.04) 77.98 159 1.90 (1.62–2.22) 116.16
Leukaemias (204–208) 74 0.98 (0.77–1.23)  0.71 14 1.29 (0.71–2.17) 9.18 33 1.58 (1.09–2.37) 18.62
Other smoking-related cancers 382 1.07 (0.96–1.18) 11.56 57 1.14 (0.87–1.48) 21.01 132 1.45 (1.21–1.72) 62.99
Colorectal (153, 154) 395 1.01 (0.92–1.12) 1.84 46 0.79 (0.58–1.05)  35.66 129 1.15 (0.96–1.38) 25.91
Colon (153) 223 1.00 (0.87–1.14) 0.00 29 0.85 (0.57–1.22)  14.92 81 1.24 (0.98–1.57) 24.14
Rectum (154) 172 1.04 (0.89–1.21) 3.11 17 0.70 (0.41–1.13)  21.25 48 1.02 (0.76–1.36) 1.45
Non-smoking-related cancer 1033 0.96 (0.90–1.02)  20.48 176 1.09 (1.21–1.58) 44.48 455 1.39 (1.26–1.52) 195.41
Prostate (185) 694 1.06 (0.98–1.14) 18.49 111 1.19 (0.98–1.43) 51.68 312 1.56 (1.39–1.79) 172.37
Testis (186) 5 1.10 (0.36–2.56) 0.21 1 1.26 (0.03–6.99) 0.60 5 3.14 (1.01–9.55) 5.25
Thyroid gland (193) 10 1.14 (0.55–2.10) 0.58 4 3.04 (0.83–7.79) 7.83 9 3.43 (1.57–8.62) 9.82
Other non-smoking-related cancers 324 0.79 (0.71–0.88)  39.77 60 0.92 (0.70–1.18)  15.63 129 1.04 (0.87–1.24) 7.98
Abbreviations: CI¼confidence interval; ICD¼International Classification of Disease; Obs¼observed number; PY¼person-years. Smoking-related cancers included: head
and neck (ICD-9: lip: 140, tongue: 141, mouth: 143–145, oropharynx: 146, hypopharynx: 148, pharynx unspecified: 149, and larynx: 161), salivary gland (142), nasopharynx
(147), oesophagus (150), nose and nasal cavity (160), stomach (151), liver (155), and pancreas (157), bladder and kidney (188189), leukaemia (204–208). AER is expressed
as per 100000.
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are presented in Appendix Table A2. The 25-year cumulative
risks among SCLC patients were low: among women, 0.51%
developed smoking-related SPCs and 0.84% developed non-
smoking-related SPCs; among men, the rates were 0.58 and
0.70%, respectively. Among SCC and ADC cases, men had
higher smoking-related SPC risk than women: 1.64% (95% CI¼
1.54–1.73) vs 0.96% (95% CI¼0.78–1.13) among SCC patients
and 1.35% (95% CI¼1.21–1.50) vs 1.02% (95% CI¼0.80–1.24)
among ADC patients. In terms of non-smoking-related SPCs,
women and men had similar 25-year cumulative risks (1.77%, 95%
CI¼1.46–2.08 for women and 1.69%, 95% CI¼1.60–1.79 for
men) among SCC cases, but women had a higher cumulative risk
among ADC cases (2.32%, 95% CI¼2.03–2.60 for women and
1.87%, 95% CI¼1.69–2.05 for men).
Figure 2 presents the SIRs of second primary female breast
and prostate cancer by age at diagnosis of the first primary
lung ADC and SCC. We observed associations with second
primary breast cancer for those whose first primary lung ADC
was diagnosed at younger age (SIR¼1.43, 95% CI¼1.03–1.92 for
o56 years of age; and SIR¼1.40, 95% CI¼1.04–1.84 for
56–65 years of age). Such an association was not observed among
cases of first primary lung SCC. The associations between ADC
and second primary prostate cancer were present in all age
strata but decreased slightly in the older age groups. There were
similar associations with ovarian cancer for women diagnosed with
first primary lung ADC below 56 years of age (observed N¼12,
SIR¼2.25, 95% CI¼1.16–3.94); second primary testicular cancer
was associated with first primary lung ADC only among those
who were 56–65 years of age at first cancer registration
(observed N¼3).
Appendix Table A3 lists SIRs for selected SPCs by calendar
period and histology. Overall, the SIRs for smoking-related SPCs
for women were 2.33 (95% CI¼1.73–3.07) before 1975, 2.37 (95%
CI¼1.94–2.86) between 1975 and 1983, 2.35 (95% CI¼1.95–2.81)
between 1984 and 1990, and 2.03 (95% CI¼1.62–2.52) after
1990; the corresponding SIRs within the same calendar period for
men were 1.44 (95% CI¼1.31–1.58), 1.59 (95% CI¼1.47–1.71),
1.63 (95% CI¼1.40–1.77), and 1.72 (95% CI¼1.55–1.91),
respectively.
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among male lung cancer patients
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cancers among male lung cancer patients
ADC
SCC
SCLC
Cumulative risk of non-smoking-related
cancers among female lung cancer patients
ADC
SCC
SCLC
A B
C D
Figure 1 Cumulative risks of selected second primary cancer following a first primary lung cancer, taking death into account as the competing risk. ADC,
adenocarcinoma; SCC, squamous cell lung carcinoma; SCLC, small cell carcinoma. A: smoking-related SPCs among female patients; B: non-smoking-related
SPCs among female patients; C: smoking-related SPCs among male patients; D: non-smoking-related SPCs among male patients.
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Figure 2 Standardised incidence ratios (SIRs) of second primary breast cancer in women and prostate cancer in men by age at diagnosis of first primary
lung adenocarcinoma and squamous cell carcinoma.
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In our study, 2% of individuals with primary lung cancer
developed an SPC during a mean follow-up period of 1.6 years,
representing excess risks of 36% for women and 25% for men.
Overall, we observed excess risks of smoking-related SPCs for
both genders in all three histological types of FPLC, as well
as some types of non-smoking-related SPCs with first primary
lung ADC.
The relative excess risks of smoking-related cancers after lung
cancer were stronger in women than in men. Although lung cancer
incidence is increasing in women, incidence rates of most
smoking-related cancers are lower in women than in men. For
example, the incidence rate per 100000 of head and neck cancer in
the year 2002 was 15.3 in men and 4.6 in women (Ferlay et al,
2004), the difference reflecting the lower incidence of primary
smoking-related cancers in women in the reference general
population; comparison of AERs shows a larger AER in men.
We observed associations between smoking-related SPCs and
first primary lung SCC and SCLC for both men and women. For
ADC, associations were observed not only with smoking-related
cancers but also with other cancers. ADC accounted for 31–54% of
lung cancers among male non-smokers and for 49–74% of lung
cancers among female non-smokers in North America (Charloux
et al, 1997), implying the involvement of non-smoking factors in
its aetiology. We observed increased SIRs for second primary
female breast and ovarian cancer after lung ADC to be more
pronounced among young women. Such an association was not
noted in first primary lung SCC and SCLC; in men, an association
between prostate and lung ADC was also observed. Because breast,
ovary, and prostate cancers are hormone-related cancers,
hormone-related factors may have a role in lung ADC aetiology.
A negative association between endometrial cancer and lung
SCC and SCLC was observed (but not with lung ADC) (Table 2),
which is consistent with its inverse association with cigarette
smoking but positive association with oestrogens (Cook et al,
2006). Although IARC has reclassified colorectal cancer as being
smoking related (Secretan et al, 2009), no association was observed
between first primary lung and second primary colorectal cancers.
Given the long induction period of smoking in colorectal
carcinogenesis and the decreased risk after the cessation of
smoking (Secretan et al, 2009), and the fact that quitting smoking
is usual among lung cancer patients, this was expected. However,
in contrast to most of the studies (Liang et al, 2009) that found a
stronger association with smoking in rectal than in colon cancers,
we observed an association between lung ADC and colon cancer,
but not with rectal cancer. Smoking has been consistently
associated with colorectal adenomatous polyps, a precancerous
lesion of colorectal cancer (Botteri et al, 2008), which might
suggest that ADCs share common risk factors. Nevertheless, such
a pattern was not observed in the association between lung ADC
and oesophageal ADC.
In our study, the SIRs for smoking-related SPCs after a first
primary SCC and SCLC did not change significantly across the
calendar years, but we observed an increasing trend for overall
smoking-related SPCs in male ADC patients (P for trend¼0.04),
suggesting a time trend between tobacco smoking and a more
important role in the development of ADC; this was not observed
in female ADC cases (P¼0.74).
The median life expectancy in untreated SCLC is about 6 to 12
weeks (Schiller, 2002). In our study, 75% of SCLC patients were
followed up for less than 1 year and the main reason for
terminating follow-up was death (97%). Fortunately, the large
sample size across the registries enabled us to explore the SPCs for
SCLC survivors who showed an excess risk for smoking-related,
but not for non-smoking-related, cancers.
A major limitation of our study is the lack of individual-based
smoking information. On the assumption that multiple cancers
share risk factors, we separated smoking and non-smoking-related
SPCs to examine the potential importance of smoking on male and
female SPC development. We could not exclude the possibility of
misclassification between metastasis and second primaries because
we did not have relevant pathological information. However,
our data were from high-quality cancer registries, 85% or over
being microscopically verified (Parkin et al, 2002). In addition, the
stratified analysis by follow-up years (data not shown) showed
relatively stable SIRs across all strata. We surmised that the
probability of an SPC being a metastasis would decrease with
longer follow-up time. Individuals with FPLC may have increased
surveillance for other smoking-related cancers, but the increased
risks of non-smoking-related sites may reflect a more general
surveillance bias. The large size of our study provided precision in
stratified analyses.
In conclusion, SCC, SCLC, and ADC were associated with
smoking-related SPCs in both men and women. Associations of
ADC in female patients at younger age with second primary breast
and ovarian cancers and of ADC in male patients with prostate
cancer may reflect a role of hormones in lung ADC aetiology.
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